ATE253375T1 - Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes - Google Patents
Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktesInfo
- Publication number
- ATE253375T1 ATE253375T1 AT98922546T AT98922546T ATE253375T1 AT E253375 T1 ATE253375 T1 AT E253375T1 AT 98922546 T AT98922546 T AT 98922546T AT 98922546 T AT98922546 T AT 98922546T AT E253375 T1 ATE253375 T1 AT E253375T1
- Authority
- AT
- Austria
- Prior art keywords
- glp
- upper gastrointestinal
- gastrointestinal tract
- methods
- tissue
- Prior art date
Links
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract 6
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 6
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 6
- 210000002438 upper gastrointestinal tract Anatomy 0.000 title abstract 5
- 239000000556 agonist Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 239000000813 peptide hormone Substances 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4675497P | 1997-05-16 | 1997-05-16 | |
| GBGB9715481.9A GB9715481D0 (en) | 1997-07-23 | 1997-07-23 | Methods of enhancing functioning of the upper gastrointestinal tract |
| US09/059,504 US6051557A (en) | 1997-05-16 | 1998-04-13 | Methods of enhancing functioning of the upper gastrointestinal tract |
| PCT/CA1998/000497 WO1998052600A1 (en) | 1997-05-16 | 1998-05-15 | Methods of enhancing functioning of the upper gastrointestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE253375T1 true ATE253375T1 (de) | 2003-11-15 |
Family
ID=27268946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98922546T ATE253375T1 (de) | 1997-05-16 | 1998-05-15 | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0981362B1 (enExample) |
| JP (2) | JP4699576B2 (enExample) |
| CN (1) | CN1264307B (enExample) |
| AT (1) | ATE253375T1 (enExample) |
| AU (1) | AU746633B2 (enExample) |
| BR (1) | BR9808804A (enExample) |
| CA (1) | CA2289652C (enExample) |
| DE (1) | DE69819488T2 (enExample) |
| DK (1) | DK0981362T3 (enExample) |
| ES (1) | ES2210756T3 (enExample) |
| MX (1) | MXPA99010523A (enExample) |
| PT (1) | PT981362E (enExample) |
| WO (1) | WO1998052600A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE253375T1 (de) * | 1997-05-16 | 2003-11-15 | Ontario Inc 1149336 | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
| GB9905416D0 (en) * | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
| RU2164349C1 (ru) * | 1999-07-27 | 2001-03-20 | Нижегородская государственная медицинская академия | Способ определения стоматологического статуса |
| WO2001041779A2 (en) * | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| PT1326630E (pt) * | 2000-09-18 | 2008-09-02 | Sanos Bioscience As | Utilização de péptidos glp-2 |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| DK1809318T3 (da) | 2004-11-01 | 2013-09-08 | Nps Pharma Inc | Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet |
| DE602006020123D1 (de) † | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| JP5908478B2 (ja) * | 2010-08-30 | 2016-04-26 | エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成 |
| EA028929B1 (ru) | 2012-05-03 | 2018-01-31 | Зилэнд Фарма А/С | Аналоги глюкагоноподобного пептида-2 (glp-2) |
| US20180200301A1 (en) * | 2015-05-21 | 2018-07-19 | Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences | Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| IL271245B2 (en) | 2017-06-16 | 2023-10-01 | Zealand Pharma As | Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2 |
| CN108273038B (zh) * | 2018-03-16 | 2019-03-19 | 中国人民解放军军事科学院军事医学研究院 | 防治肠型放射病的药物组合物 |
| CN110226566A (zh) * | 2019-07-12 | 2019-09-13 | 南京中医药大学 | 一种放射性口腔黏膜炎动物模型的造模方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK27885A (da) * | 1985-01-22 | 1986-07-23 | Novo Industri As | Fremstilling af peptider |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| EP2275438A1 (en) * | 1996-04-12 | 2011-01-19 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
| ES2181054T3 (es) * | 1996-12-06 | 2003-02-16 | Amgen Inc | Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento. |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| ATE253375T1 (de) * | 1997-05-16 | 2003-11-15 | Ontario Inc 1149336 | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
-
1998
- 1998-05-15 AT AT98922546T patent/ATE253375T1/de active
- 1998-05-15 JP JP54974198A patent/JP4699576B2/ja not_active Expired - Fee Related
- 1998-05-15 BR BR9808804-1A patent/BR9808804A/pt not_active Application Discontinuation
- 1998-05-15 EP EP98922546A patent/EP0981362B1/en not_active Expired - Lifetime
- 1998-05-15 WO PCT/CA1998/000497 patent/WO1998052600A1/en not_active Ceased
- 1998-05-15 CN CN988073307A patent/CN1264307B/zh not_active Expired - Fee Related
- 1998-05-15 AU AU75163/98A patent/AU746633B2/en not_active Ceased
- 1998-05-15 DE DE69819488T patent/DE69819488T2/de not_active Expired - Lifetime
- 1998-05-15 PT PT98922546T patent/PT981362E/pt unknown
- 1998-05-15 MX MXPA99010523A patent/MXPA99010523A/es active IP Right Grant
- 1998-05-15 DK DK98922546T patent/DK0981362T3/da active
- 1998-05-15 ES ES98922546T patent/ES2210756T3/es not_active Expired - Lifetime
- 1998-05-15 CA CA2289652A patent/CA2289652C/en not_active Expired - Fee Related
-
2009
- 2009-07-22 JP JP2009171401A patent/JP2009280598A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998052600A9 (en) | 2000-03-09 |
| DE69819488D1 (de) | 2003-12-11 |
| AU746633B2 (en) | 2002-05-02 |
| CA2289652A1 (en) | 1998-11-26 |
| DE69819488T2 (de) | 2004-08-26 |
| ES2210756T3 (es) | 2004-07-01 |
| MXPA99010523A (es) | 2004-09-01 |
| AU7516398A (en) | 1998-12-11 |
| EP0981362A1 (en) | 2000-03-01 |
| BR9808804A (pt) | 2001-09-18 |
| JP2002502369A (ja) | 2002-01-22 |
| EP0981362B1 (en) | 2003-11-05 |
| CN1264307B (zh) | 2013-10-30 |
| HK1030160A1 (en) | 2001-04-27 |
| CN1264307A (zh) | 2000-08-23 |
| PT981362E (pt) | 2004-03-31 |
| JP2009280598A (ja) | 2009-12-03 |
| WO1998052600A1 (en) | 1998-11-26 |
| JP4699576B2 (ja) | 2011-06-15 |
| CA2289652C (en) | 2012-02-28 |
| DK0981362T3 (da) | 2004-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69819488D1 (de) | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes | |
| ATE233096T1 (de) | Zusammensetzungen und methoden zur steigerung der darmfunktion | |
| Lundy et al. | Neuropeptides and neurogenic mechanisms in oral and periodontal inflammation | |
| UA42747C2 (uk) | Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту | |
| ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
| DE69914932D1 (de) | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis | |
| DE69736634D1 (de) | Antagonisten des intestinotrophen glp-2 peptides | |
| DE69521796D1 (de) | Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes | |
| TR199801649T2 (xx) | Ba����kl�k mod�lasyonu i�in farmaz�tik bile�imler. | |
| HUP0004560A2 (hu) | Törést gyógyító PTHrP analógok | |
| WO1998033509A3 (en) | Useful properties of human lactoferrin and variants thereof | |
| DE60118723D1 (de) | Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten | |
| ATE531382T1 (de) | Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen | |
| DE69435096D1 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
| EA200400376A1 (ru) | Пептиды, полученные из казеина, и их использование в терапии | |
| EA200100872A1 (ru) | Композиция валдекоксиба | |
| DE69607750D1 (de) | Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung | |
| ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
| DE60237158D1 (de) | Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen | |
| WO2004027064A3 (en) | Ghrh analogues | |
| DE69533704D1 (de) | Bradykinin-antagonist peptide mit n-substituierten glycinen | |
| JP2006506942A5 (enExample) | ||
| ATE425763T1 (de) | Verwendung von zusammensetzungen mit der biologischen aktivitat der vasoaktiven intestinalen peptide zur behandlung von sarcoidose | |
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
| NO20011537L (no) | Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0981362 Country of ref document: EP |